Beyond the 25% weight loss headline, OB_Health points to four other trial figures it says matter when judging retatrutide.
Recap by typeshit. Full story at OB_Health.
A physio fielding years of peptide questions says strong studies are lacking, while noting that a lack of evidence doesn't prove they fail.
Up to half of participants in the two trials of the experimental drug ended up with only mild sleep apnea, per the post.
Nippard puts the two approved drugs on top for supervised weight loss and holds retatrutide at B-tier until it is approved.
Bloomberg traces how Amgen used genetic data from Iceland to guide its obesity drug research.
Scientists push back on 'natural means safe' messaging for BPC-157, and some new FDA panel members who backed looser rules sell peptides themselves.
Ryan writes that chemo left him with 25 pounds he couldn't lose despite hours at the gym, and that the experience overturned his belief that fat people lack discipline.
Loading…